New Frontiers in the Targeted Treatment of Myelofibrosis


This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an educational grant from GlaxoSmithKline.


Myelofibrosis (MF) is a rare, chronic myeloproliferative neoplasm (MPN) occurring de novo (primary) or secondary to polycythemia vera or essential thrombocythemia. MF is associated with high heterogeneity and a variable clinical course, such that risk stratification is an essential component of the initial diagnosis. Advances in our understanding of the molecular characteristics of MF have resulted in a multitude of risk stratification models, the availability of which may, however, pose significant challenges to clinicians, especially in the community setting. Clinicians also face the challenge of evolving treatment options.

Drs. Mesa and Gerds review the most impactful publications related to patients diagnosed with MF that are experiencing anemia and thrombocytopenia. A reading list and key slides are available for download.


Aaron T. Gerds, MD, MS
Associate Professor of Medicine
Hematology and Medical Oncology
Deputy Director for Clinical Research
Medical Director, Case Comprehensive Cancer Center
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Ruben Mesa, MD
President, Levine Cancer Institute & Enterprise Cancer Service Line
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President, Atrium Health
Vice Dean for Cancer Programs, Wake Forest University School of Medicine
Professor of Medicine, Wake Forest University School of Medicine
Winston-Salem, North Carolina

Release date: June 9, 2023
Expiration date: June 9, 2024
Estimated time to complete activity: 45 minutes

This activity has been developed to meet the professional needs of medical oncologists and hematologists, as well as other healthcare professionals who treat and manage patients with hematologic malignancies.


Upon completion of this educational activity, participants should be able to:

  • Summarize clinical trial data on the safety and efficacy of new and emerging therapies for the treatment of MF
  • Utilize recent clinical trial evidence and current guideline recommendations to improve disease control in patients with MF

There are no fees for participating and receiving CME credit for this activity. During the period of June 9, 2023 through June 9, 2024 participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Aaron T. Gerds, MD, MS
Consultant: AbbVie, Bristol Myers Squibb, CTI Biopharma, GlaxoSmithKline/Sierra Oncology, Imago, Morphosys, Novartis, PharmaEssentia

Ruben Mesa, MD
Consultant: Abbvie, Blueprint, Bristol Myers Squibb, CTI BioPharma, GlaxoSmithKline, Genentech, Geron, Incyte, Morphosys, Novartis, Sierra, Sierra Oncology, Telios

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest